Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:ELVN NASDAQ:GPCR NASDAQ:INKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$4.50-2.4%$3.88$3.21▼$7.18$1.10B0.64.42 million shs3.04 million shsELVNEnliven Therapeutics$21.65-5.9%$19.86$13.30▼$30.03$1.13B0.83302,756 shs900,984 shsGPCRStructure Therapeutics$19.23-1.7%$22.14$13.22▼$47.48$1.12B-1.87834,652 shs1.10 million shsINKTMiNK Therapeutics$28.01-31.0%$9.52$4.56▼$76.00$161.86M0.19229,425 shs1.47 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-2.39%+0.45%+25.00%-2.17%-24.37%ELVNEnliven Therapeutics-5.87%+8.63%-1.19%+34.72%-13.75%GPCRStructure Therapeutics-1.74%+2.61%-11.30%+3.78%-56.81%INKTMiNK Therapeutics-31.03%+289.03%+283.17%+257.73%+145.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.0655 of 5 stars3.51.00.04.42.62.50.6ELVNEnliven Therapeutics2.7955 of 5 stars3.52.00.00.02.54.20.0GPCRStructure Therapeutics2.9103 of 5 stars3.53.00.00.03.21.70.6INKTMiNK Therapeutics2.5049 of 5 stars3.23.00.00.02.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$10.89141.98% UpsideELVNEnliven Therapeutics 3.00Buy$41.2090.30% UpsideGPCRStructure Therapeutics 3.00Buy$76.17296.08% UpsideINKTMiNK Therapeutics 2.33Hold$37.5033.88% UpsideCurrent Analyst Ratings BreakdownLatest INKT, ELVN, GPCR, and ARDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.007/11/2025INKTMiNK TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/2/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.006/23/2025GPCRStructure TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$65.006/23/2025GPCRStructure TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$89.006/18/2025ARDXArdelyxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.006/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/12/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $75.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M3.23N/AN/A$0.73 per share6.16ELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$15.10 per shareN/AINKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A14.52N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)ELVNEnliven Therapeutics-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)GPCRStructure Therapeutics-$122.53M-$0.87N/AN/AN/AN/A-16.35%-15.71%8/6/2025 (Estimated)INKTMiNK Therapeutics-$9.51M-$2.52N/AN/AN/AN/AN/A-140.72%8/12/2025 (Estimated)Latest INKT, ELVN, GPCR, and ARDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ELVNEnliven Therapeutics-$0.54N/AN/AN/AN/AN/A8/12/2025Q2 2025INKTMiNK Therapeutics-$0.45N/AN/AN/AN/AN/A8/7/2025Q2 2025ARDXArdelyx-$0.12N/AN/AN/AN/AN/A5/15/2025Q1 2025INKTMiNK Therapeutics-$0.61-$0.70-$0.09-$0.70N/AN/A5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24-$0.27-$0.03-$0.27N/AN/A5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.044.123.81ELVNEnliven TherapeuticsN/A21.0721.06GPCRStructure TherapeuticsN/A23.2923.29INKTMiNK TherapeuticsN/A0.300.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%ELVNEnliven Therapeutics95.08%GPCRStructure Therapeutics91.78%INKTMiNK Therapeutics2.87%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%ELVNEnliven Therapeutics25.90%GPCRStructure Therapeutics9.43%INKTMiNK Therapeutics22.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million227.77 millionOptionableELVNEnliven Therapeutics5049.07 million36.36 millionOptionableGPCRStructure Therapeutics13657.34 million51.94 millionOptionableINKTMiNK Therapeutics303.99 million3.09 millionNo DataINKT, ELVN, GPCR, and ARDX HeadlinesRecent News About These CompaniesHC Wainwright Reiterates Neutral Rating for MiNK Therapeutics (NASDAQ:INKT)July 15 at 11:19 AM | marketbeat.comMiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell TherapyJuly 15 at 8:42 AM | globenewswire.comMiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell TherapyJuly 15 at 8:42 AM | globenewswire.comMiNK Therapeutics Enters $50M Sales Agreement with B. RileyJuly 15 at 7:48 AM | tipranks.comMiNK Therapeutics Shares Drop Sharply Following William Blair DowngradeJuly 14 at 11:58 AM | msn.comMiNK Therapeutics stock falls after William Blair downgradeJuly 14 at 11:58 AM | finance.yahoo.comPromising Small Cap Stocks To Watch Now - July 13thJuly 13 at 4:06 PM | marketbeat.comPharmaceutical Stocks Worth Watching - July 13thJuly 13 at 4:06 PM | marketbeat.comMiNK Therapeutics Announces Publication of Complete Remission Following ...July 13 at 3:55 PM | seekingalpha.comMiNK Therapeutics: AgenT-797 Solidifies Itself As iNKT Cell Therapy With Latest CR DataJuly 13 at 3:55 PM | seekingalpha.comPromising Medical Stocks To Add to Your Watchlist - July 13thJuly 13 at 2:00 PM | marketbeat.comWhy Is MiNK Therapeutics Stock (INKT) Up 190% Today?July 12, 2025 | msn.comMiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell ...July 11, 2025 | bakersfield.comBMiNK Therapeutics stock soars after cancer remission breakthroughJuly 11, 2025 | investing.comWhy Did INKT Stock Skyrocket in Today’s Premarket Trading?July 11, 2025 | tokenist.comTMiNK Therapeutics Shares Surge After Remission Case Published in Scientific JournalJuly 11, 2025 | marketwatch.comMiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell TherapyJuly 11, 2025 | msn.comMiNK Therapeutics Shares Skyrocket After Landmark Cancer Remission ResultJuly 11, 2025 | msn.comBest Small Cap Stocks To Watch Today - July 11thJuly 11, 2025 | marketbeat.comPharmaceutical Stocks To Keep An Eye On - July 11thJuly 11, 2025 | marketbeat.comBest Medical Stocks To Keep An Eye On - July 11thJuly 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINKT, ELVN, GPCR, and ARDX Company DescriptionsArdelyx NASDAQ:ARDX$4.50 -0.11 (-2.39%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$4.46 -0.04 (-0.89%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Enliven Therapeutics NASDAQ:ELVN$21.65 -1.35 (-5.87%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$23.00 +1.35 (+6.24%) As of 07/15/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Structure Therapeutics NASDAQ:GPCR$19.23 -0.34 (-1.74%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$19.68 +0.45 (+2.37%) As of 07/15/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.MiNK Therapeutics NASDAQ:INKT$28.01 -12.60 (-31.03%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$28.07 +0.06 (+0.21%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
